Tanios Bekaii-Saab, MD, FACP, FASCO - Raising the Game in Biliary Cancer: Adapting Rapidly Emerging Evidence and Achieving Optimal Disease Control With FGFR-Targeted Platforms

About this episode

The episode discusses advancements in biliary cancer treatment and the role of FGFR-targeted platforms in achieving optimal disease control.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups. For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/ACV865. CME credit will be available until March 31, 2027. Raising the Game in Biliary Cancer: Adapting Rapidly Emerging Evidence and Achieving Optimal Disease Control With FGFR-Targeted Platforms In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Support This activity is supported by an educational grant from Incyte Corporation. Disclosure information is available at the beginning of the video presentation.

People in this episode

Guest: Tanios Bekaii-Saab, MD, FACP, FASCO

Topics covered

• biliary cancer
• FGFR-targeted platforms
• disease control
• emerging evidence
• healthcare education

Keywords

• biliary cancer
• FGFR-targeted therapy
• disease control
• healthcare professionals
• continuing education

Sponsors

Incyte Corporation

Mentioned in this episode

Organizations: PVI, PeerView Institute for Medical Education, Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), American Nurses Credentialing Center (ANCC)

More episodes of PeerView Gastroenterology CME/CNE/CPE Video Podcast

• Anita Afzali, MD, MPH, MHCM, FACG, AGAF / Jessica R. Allegretti, MD, MPH, FACG, AGAF / Millie D. Long, MD, MPH - At the Crossroads of Inflammation and Fibrosis in Inflammatory Bowel Disease: The Promise of TL1A Inhibition · May 29, 2026 · 1h 11m
• Eileen M. O'Reilly, MD, FASCO - Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management · May 12, 2026 · 52 min
• Yelena Y. Janjigian, MD*, Marion Liu, MD - Unifying Surgical-Oncology Expertise in Resectable Gastric/GEJ Malignancies: Leveraging the Evidence on Perioperative Immunotherapy Platforms to Deliver Personalized Care · April 3, 2026 · 1h 4m
• Mrinal Gounder, MD - Paving the Path Forward for Desmoid Tumors: Multidisciplinary Tactics to Effectively Implement Gamma Secretase Inhibitors in Clinical Practice · April 1, 2026 · 1h 0m
• Samuel Cytryn, MD / Daniela Molena, MD / Manish A. Shah, MD, FASCO - Synchronizing Success in Resectable Gastric/GEJ Cancer: Merging Expertise to Effectively Deliver Immunotherapy Platforms in the Surgical Setting · March 4, 2026 · 1h 0m
• Prof. Dr. Peter R. Galle - Streamlining Multidirectional Care in HCC: Applying Groundbreaking Evidence on Systemic Treatment Approaches Across the Disease Spectrum · February 12, 2026 · 1h 33m